NJ Bio

NJ Bio, Inc. is a contract research organization and integrated drug development partner serving biopharmaceutical and chemistry-based technology companies. It supports programs from discovery and rapid proof of concept through development, testing, and GMP manufacturing, with flexible engagement models including FTE, milestone-based, and blended arrangements.

Its services span antibody-drug conjugates (ADCs), bioconjugation, payload and linker design and manufacturing, medicinal chemistry, custom synthesis, and protein degraders. NJ Bio also provides end-to-end mRNA synthesis, oligonucleotide and nucleotide development, and antibody production. Translational research capabilities include in vitro and in vivo studies, immuno-oncology work, humanized mouse models, patient-derived xenograft studies, and PK/PD assessments. Analytical and characterization services cover method development and validation, stability testing, bioanalysis, functional assays, and BioNMR structural analysis.

For clinical-stage programs, NJ Bio offers GMP manufacturing for Phase 1 and Phase 2 trials, including process development, drug substance production, analytical support, and quality services. Its integrated capabilities are designed to help clients advance complex molecules and reduce early development risk.